Number of Employees: Approximately 2,400
Marlboro, L&M, Chesterfield, f6
Welcome to Philip Morris Germany (PMG). Established in 1972 we have since grown to become the leading tobacco company in Germany. After Germany’s re-unification in 1990, our operations continued to expand when f6, a leading East German cigarette brand, became part of our portfolio.
Today our organization operates throughout Germany. Our headquarters in Munich and our production facilities in Berlin and Dresden employ over 2,400 people. Our factory in Berlin is now the largest Philip Morris manufacturing facility in Europe.
We believe that we can play an important part in the local community by contributing to charitable programs in the areas where our employees live and work. We therefore fund and partner with local organizations that focus on helping disabled persons and socially disadvantaged people, as well as those suffering from domestic violence.
Smoking and Health
Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.
All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in public places.
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.
To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain. Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes.
While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, point of sale display bans, total bans on communications to adult consumers, and bans on the use of all ingredients in tobacco products.